TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.94
+8.84%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 309.43x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.31x
- Price / sales
- 234.05x
- Price / cash flow
- -9.71x
Enterprise value
- Enterprise value
- $883.9M
- EV / sales
- 161.15x
- EV / EBITDA
- -5.94x
- EV / EBIT
- -5.77x
- Market cap
- $1.3B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026